• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用动力学和X射线晶体学研究分析蛋白酶体抑制剂的特性。

Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.

作者信息

Gallastegui Nerea, Groll Michael

机构信息

Department of Biochemistry, Technische Universität München, Garching, Germany.

出版信息

Methods Mol Biol. 2012;832:373-90. doi: 10.1007/978-1-61779-474-2_26.

DOI:10.1007/978-1-61779-474-2_26
PMID:22350899
Abstract

The combination of X-ray crystallography and kinetic studies of proteasome:ligand complexes has proven to be an important tool in inhibitor analysis of this crucial protein degradation machinery. Here, we describe in detail the purification protocols, proteolytic activity assays, crystallisation methods, and structure determination for the yeast 20S proteasome (CP) in complex with its inhibitors. The fusion of these advanced techniques offers the opportunity to further optimise drugs which are already tested in different clinical phase studies, as well as to design new promising proteasome lead structures which might be suitable for their application in medicine, plant protection, and antibiotics.

摘要

X射线晶体学与蛋白酶体:配体复合物的动力学研究相结合,已被证明是分析这一关键蛋白质降解机制抑制剂的重要工具。在此,我们详细描述了与抑制剂结合的酵母20S蛋白酶体(CP)的纯化方案、蛋白水解活性测定、结晶方法和结构测定。这些先进技术的融合为进一步优化已在不同临床阶段研究中进行测试的药物提供了机会,同时也为设计新的有前景的蛋白酶体先导结构提供了机会,这些结构可能适用于医学、植物保护和抗生素领域。

相似文献

1
Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.利用动力学和X射线晶体学研究分析蛋白酶体抑制剂的特性。
Methods Mol Biol. 2012;832:373-90. doi: 10.1007/978-1-61779-474-2_26.
2
Novel proteasome inhibitors to overcome bortezomib resistance.新型蛋白酶体抑制剂克服硼替佐米耐药性。
J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23.
3
Discovery and development of second-generation proteasome inhibitors.第二代蛋白酶体抑制剂的发现和研发。
Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007.
4
[Development and clinical application of novel proteasome inhibitors].新型蛋白酶体抑制剂的研发与临床应用
Rinsho Ketsueki. 2012 Apr;53(4):417-25.
5
Second Generation Proteasome Inhibitors in Multiple Myeloma.第二代蛋白酶体抑制剂在多发性骨髓瘤中的应用
Anticancer Agents Med Chem. 2017;17(7):920-926. doi: 10.2174/1871520616666160902101622.
6
Purification, crystallization, and X-ray analysis of the yeast 20S proteasome.酵母20S蛋白酶体的纯化、结晶及X射线分析
Methods Enzymol. 2005;398:329-36. doi: 10.1016/S0076-6879(05)98027-0.
7
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.一种新型口服活性蛋白酶体抑制剂通过不同于硼替佐米的机制诱导多发性骨髓瘤细胞凋亡。
Cancer Cell. 2005 Nov;8(5):407-19. doi: 10.1016/j.ccr.2005.10.013.
8
Exploiting nature's rich source of proteasome inhibitors as starting points in drug development.利用天然丰富的蛋白酶体抑制剂作为药物开发的起点。
Chem Commun (Camb). 2012 Feb 1;48(10):1364-78. doi: 10.1039/c1cc15273d. Epub 2011 Oct 31.
9
Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.免疫和组成型蛋白酶体抑制剂:药物开发的现状和未来趋势。
Angew Chem Int Ed Engl. 2012 Aug 27;51(35):8708-20. doi: 10.1002/anie.201201616. Epub 2012 Jun 18.
10
Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.硼替佐米耐药突变蛋白酶体:用卡非佐米和ONX 0914进行的结构与生化评估
Structure. 2015 Feb 3;23(2):407-17. doi: 10.1016/j.str.2014.11.019. Epub 2015 Jan 15.

引用本文的文献

1
Global analysis of biosynthetic gene clusters reveals conserved and unique natural products in entomopathogenic nematode-symbiotic bacteria.全球生物合成基因簇分析揭示了昆虫病原线虫共生细菌中保守和独特的天然产物。
Nat Chem. 2022 Jun;14(6):701-712. doi: 10.1038/s41557-022-00923-2. Epub 2022 Apr 25.
2
Structure-Based Design of Inhibitors Selective for Human Proteasome β2c or β2i Subunits.基于结构的选择性人蛋白酶体β2c 或β2i 亚基抑制剂的设计。
J Med Chem. 2019 Feb 14;62(3):1626-1642. doi: 10.1021/acs.jmedchem.8b01884. Epub 2019 Feb 5.
3
Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.
基于胱硫醚酶的β-内酰胺的设计、合成与评价作为有效的蛋白酶体抑制剂。
Eur J Med Chem. 2018 Sep 5;157:962-977. doi: 10.1016/j.ejmech.2018.08.052. Epub 2018 Aug 20.
4
(-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study.(-)-Homosalinosporamide A 及其蛋白酶体抑制模式:X 射线晶体学研究。
Mar Drugs. 2018 Jul 19;16(7):240. doi: 10.3390/md16070240.
5
Electrostatic Map Of Proteasome α-Rings Encodes The Design of Allosteric Porphyrin-Based Inhibitors Able To Affect 20S Conformation By Cooperative Binding.蛋白酶体 α 环的静电图谱编码了别构卟啉基抑制剂的设计,这些抑制剂能够通过协同结合来影响 20S 构象。
Sci Rep. 2017 Dec 6;7(1):17098. doi: 10.1038/s41598-017-17008-7.
6
Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome - insights into the enzyme activation mechanism.低分子量激活剂 Blm-pep 与酵母 20S 蛋白酶体的晶体结构 - 对酶激活机制的深入了解。
Sci Rep. 2017 Jul 21;7(1):6177. doi: 10.1038/s41598-017-05997-4.
7
A humanized yeast proteasome identifies unique binding modes of inhibitors for the immunosubunit β5i.一种人源化酵母蛋白酶体确定了免疫亚基β5i抑制剂的独特结合模式。
EMBO J. 2016 Dec 1;35(23):2602-2613. doi: 10.15252/embj.201695222. Epub 2016 Oct 27.
8
A unified mechanism for proteolysis and autocatalytic activation in the 20S proteasome.20S蛋白酶体中蛋白水解和自催化激活的统一机制。
Nat Commun. 2016 Mar 11;7:10900. doi: 10.1038/ncomms10900.
9
Enzyme inhibition by hydroamination: design and mechanism of a hybrid carmaphycin-syringolin enone proteasome inhibitor.通过氢胺化反应实现的酶抑制作用:一种卡马霉素 - 丁香霉素烯酮杂合蛋白酶体抑制剂的设计与作用机制
Chem Biol. 2014 Jun 19;21(6):782-91. doi: 10.1016/j.chembiol.2014.04.010. Epub 2014 Jun 12.